GSK awards milestone payment to Isis Pharmaceuticals to develop ISIS-GSK4Rx for ocular disease

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Oct 1 2014Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1.5 million milestone payment from GSK related to the advancement of the program to develop ISIS-GSK4Rx to treat an undisclosed ocular disease.

"Our collaboration with GSK has been very productive resulting in four drugs in development," said B. Lynne Parshall, chief operating officer at Isis. "We look forward to advancing ISIS-GSK4Rx into clinical development and providing more information on the target and disease opportunity, which we are very excited about."

 

 

Source:

Isis Pharmaceuticals, Inc.

Posted in: Business / Finance | Disease/Infection News

Tags: , , ,

Comments (0)

Suggested Reading

SickKids study offers new path for pediatric rare disease clinical trials
Supply chain assessment and management, optimizing pharmaceutical supply chains
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
LabVantage celebrates customer success with record number of software deployments in FY 2024
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
Lancet Commission predicts sharp increase in global prostate cancer cases
Study highlights global fertility decline and its implications for the future
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals